Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Psl exopolysaccharide is a neutral exopolysaccharide synthesized by the *pslA-O* operon in *Pseudomonas aeruginosa*. It is essential for initial surface attachment and the maintenance of biofilm microstructure, providing mechanical stability and protection against antimicrobials and the host immune system. Psl is composed primarily of mannose, galactose, glucose, and rhamnose in a pentasaccharide repeating unit and is a major target for strategies aiming to prevent or disrupt biofilm-mediated infections, especially in cystic fibrosis and hospital-acquired infections[1][3][4][6][7].
Agents targeting Psl may inhibit exopolysaccharide synthesis (e.g., inhibitors of the Psl synthetic operon), disrupt established biofilm matrices, or enhance susceptibility of bacteria to antibiotics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Psl exopolysaccharide (Psl).